Biotech
Atkis Oncology
Atkis Oncology raises $175M Series B at $800M valuation
Boston, MASeptember 30, 20241 min read
Total Raised
$175M
Valuation
$800M
Latest Round
Series B
Employees
90+
Atkis Oncology: Series B Funding Round
Atkis Oncology has successfully raised $175M in Series B funding, reaching a valuation of $800M.
Company Overview
Developing precision oncology therapeutics
Funding Details
The Series B round was led by RA Capital Management, with participation from RTW Investments.
Company Information
- Headquarters: Boston, MA
- Founded: 2023
- Employees: 90+
- Category: Biotech
Investment
Atkis Oncology plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- RA Capital Management: Verified investor in Series B
- RTW Investments: Verified investor in Series B
Company Info
Headquarters
Boston, MA
Founded
2023
Team Size
90+
Last Round
$175M(Sep 2024)
Investors (2)
R
RA Capital ManagementLeadLead Investor
Verified investor in Series B
R
RTW InvestmentsInvestor
Verified investor in Series B
Share
Related Reports
Biotech
AusperBio
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free